Children's Brain Tumor Foundation explains the importance of their research and programs.
Why is it so important to support CBTF's research and programs? Watch this video featuring families, survivors, and some of our greatest supporters to find out why.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
March 6th 2024The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.